{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:15:58Z","timestamp":1790842558521,"version":"4.1.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, neuroinflammation, and oxidative stress. Current treatments are largely symptomatic, necessitating novel neuroprotective strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the anti-inflammatory and antioxidant effects of chitosan-cannabidiol (CS-CBD) nanoparticles in a streptozotocin (STZ)-induced rat model of AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty male Wistar rats were randomly divided into five groups: control, AD model (STZ-induced), chitosan-treated, cannabidiol-treated, and CS-CBD-treated. AD was induced by intracerebroventricular injection of STZ (3 mg\/kg). Treatments were administered intranasally for 21 days. Cognitive performance was assessed using the Morris water maze. After treatment, oxidative stress markers (NO, FRAP), liver enzymes (ALT, AST), and the expression of inflammatory and neuroprotective genes (IL1\u03b2, IL6, IL10, iNOS, PPAR\u03b3, BDNF) were evaluated by real-time PCR. Histological analysis of the hippocampus was also performed. Data were analyzed using one-way ANOVA and Tukey's post hoc test (p\u2009&lt;\u20090.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The AD group showed significant impairments in memory and learning (p\u2009&lt;\u20090.0001), increased oxidative stress, and upregulation of pro-inflammatory genes (IL1\u03b2, iNOS), with decreased neuroprotective markers (BDNF, PPAR\u03b3). CS-CBD treatment significantly improved cognitive function (p\u2009&lt;\u20090.001), restored oxidative balance, reduced IL1\u03b2 and iNOS expression, and elevated BDNF and PPAR\u03b3 expression (p\u2009&lt;\u20090.05). Histological analysis confirmed reduced neuronal degeneration and increased neuronal density in the CS-CBD group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CS-CBD nanoparticles exerted potent neuroprotective, antioxidant, and anti-inflammatory effects in an STZ-induced rat model of AD. These findings support the potential of CS-CBD nanoparticles as a promising adjunctive therapy for AD, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251379420","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:37:58Z","timestamp":1758721078000},"page":"790-804","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Synergistic neuroprotection of chitosan-cannabidiol nanoparticles in a rat model of Alzheimer's disease: Amelioration of cognitive deficits and neuroinflammation"],"prefix":"10.1177","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8575-7991","authenticated-orcid":false,"given":"Zahra","family":"Naserramezani","sequence":"first","affiliation":[{"name":"Department of Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-944X","authenticated-orcid":false,"given":"Mohammad Reza","family":"Palizvan","sequence":"additional","affiliation":[{"name":"Department of Physiology, School of Medicine, Arak University of Medical Sciences, Arak, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2632-9889","authenticated-orcid":false,"given":"Ali","family":"Ganji","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran"},{"name":"Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-9594","authenticated-orcid":false,"given":"Ali","family":"Ghazavi","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran"},{"name":"Traditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical Sciences, Arak, Iran"},{"name":"Infectious Diseases Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3877-0783","authenticated-orcid":false,"given":"Ghasem","family":"Mosayebi","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran"},{"name":"Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"109","article-title":"Effects of donepezil hydrochloride on neuronal response of pyramidal neurons of the CA1 hippocampus in rat model of Alzheimer's disease","volume":"10","author":"Eskandary A","year":"2019","unstructured":"Eskandary A, Moazedi AA, Najaph Zade H, et al. Effects of donepezil hydrochloride on neuronal response of pyramidal neurons of the CA1 hippocampus in rat model of Alzheimer's disease. Basic Clin Neurosci 2019; 10: 109\u2013117.","journal-title":"Basic Clin Neurosci"},{"key":"e_1_3_3_3_2","unstructured":"Prince M Albanese E Guerchet M et al. World Alzheimer Report 2014. Dementia and Risk Reduction: An analysis of protective and modifiable risk factors. London: Alzheimer's Disease International 2014."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00902"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-013-1422-z"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101208"},{"key":"e_1_3_3_7_2","first-page":"100467","article-title":"Impacts of FDA approval and medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development","volume":"20","author":"Brockmann R","year":"2023","unstructured":"Brockmann R, Nixon J, Love BL, et al. Impacts of FDA approval and medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development. Lancet Reg Health Am 2023; 20: 100467.","journal-title":"Lancet Reg Health Am"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/iji.12465"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46050266"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707337"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028668"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.117"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389557521666210331162857"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1087011"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010204"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204866"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.02.012"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1112435"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010196"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29112584"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29204854"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271138"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02836-4"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2021.173273"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.5958\/0973-3566.2021.00010.9"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10735-021-09998-6"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00402"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00079-5"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076827"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2023.0101"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076827"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102176"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9010021"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.2174\/18715273113129990072"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10091353"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9010021"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28041963"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2003.02327.x"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3897\/folmed.65.e107259"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.4274\/tji.galenos.2024.76598"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-013-9493-1"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2024.148771"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251379420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251379420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251379420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:35:36Z","timestamp":1779096936000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251379420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/13872877251379420"],"URL":"https:\/\/doi.org\/10.1177\/13872877251379420","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}